You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 283 No. 10, March 8, 2000 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (24)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

{beta}-Blocker Therapy for Heart Failure

The Evidence Is In, Now the Work Begins

Robert M. Califf, MD; Christopher M. O'Connor, MD

JAMA. 2000;283:1335-1337.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The young intern, Dr O'Connor, is beginning his rotation in the cardiac care unit in 1983. His faculty attending, Dr Califf, notices that Dr O'Connor has initiated {beta}-blockade in a patient with heart failure. The discussion that ensues does not reflect positively on Dr O'Connor's future career. In 2000, both physicians realize that their understanding of blockade of the {beta}-receptor as a simple matter of reducing myocardial contractility was shortsighted and fundamentally incorrect. Dr O'Connor had initiated the right therapy but for the wrong reason.

This issue of THE JOURNAL contains the complete results of the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF),1 including detailed quality-of-life and hospitalization data. As previously reported,2 the trial emphasizes the improvement in mortality among patients with moderate heart failure when treated with the long-acting {beta}-blocker controlled-release/extended-release metoprolol succinate (metoprolol CR/XL). (Similar survival information . . . [Full Text of this Article]

Author Affiliations: Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Efficacy, safety and tolerability of {beta}-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure
Deedwania et al.
Eur Heart J 2004;25:1300-1309.
ABSTRACT | FULL TEXT  

Improving Guideline Adherence: A Randomized Trial Evaluating Strategies to Increase {beta}-Blocker Use in Heart Failure
Ansari et al.
Circulation 2003;107:2799-2804.
ABSTRACT | FULL TEXT  

Treatment of chronic heart failure with {beta} adrenergic blockade beyond controlled clinical trials: the BRING-UP experience
Maggioni et al.
Heart 2003;89:299-305.
ABSTRACT | FULL TEXT  

Management of patients with heart failure: are internists as good as cardiologists?
Bonarjee and Dickstein
Eur Heart J 2001;22:530-531.
 

Treatment of Congestive Heart Failure: Guidelines for the Primary Care Physician and the Heart Failure Specialist
Gomberg-Maitland et al.
Arch Intern Med 2001;161:342-352.
ABSTRACT | FULL TEXT  

Spironolactone for Heart Failure : Spiraling Out of Control
Geraci and Knowlton
Chest 2000;118:1522-1523.
FULL TEXT  

Perioperative Treatment of Congestive Heart Failure
Clark
SEMIN CARDIOTHORAC VASC ANESTH 2000;4:223-235.
ABSTRACT  

The Quest to Quantify Quality
Fihn
JAMA 2000;283:1740-1742.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.